Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046320 | 1.00 | SLC6A3 (0.43) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL14046350 | 1.00 | SLC6A3 (0.43) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL14046171 | 0.85 | LMNA (0.49) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL14046256 | 0.85 | LMNA (0.49) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL14046315 | 0.85 | LMNA (0.49) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL14046312 | 0.83 | SLC6A3 (0.46) | SLC6A3KMT2AOPRM1LMNANPSR1 | |
| SCHEMBL4603488 | 0.80 | HSD11B1 (0.38) | SLC6A3KMT2AOPRM1NPSR1 | |
| SCHEMBL4602863 | 0.80 | HSD11B1 (0.38) | SLC6A3KMT2AOPRM1NPSR1 | |
| SCHEMBL14046309 | 0.80 | SLC6A3 (0.59) | SLC6A3KMT2AOPRM1LMNA | |
| SCHEMBL14046295 | 0.80 | SLC6A3 (0.59) | SLC6A3KMT2AOPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | SLC6A3 1030/4885KMT2A 3354/4885OPRM1 12/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | SLC6A3 773/4885KMT2A 3266/4885OPRM1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.